基于计算策略的金振口服液联合阿奇霉素治疗儿童支原体肺炎三臂随机对照试验
本研究先通过网络靶点分析揭示金振口服液(JZOL)与阿奇霉素(AZ)联合治疗的模块网络调控机制,再开展随机、双盲、三臂、平行对照、多中心临床试验,评估不同剂量JZOL联合AZ治疗儿童支原体肺炎(MPP)的协同效应与安全性。结果显示联合治疗可缩短病程、缓解症状、改善预后。
要点
- JZOL联合AZ可缩短MPP患儿临床恢复时间,双倍剂量组5天、常规剂量组6天、安慰剂组8天。
- 联合治疗在完全退热时间、咳嗽/咳痰缓解时间、胸片改善有效率及中医证候治愈率方面组间差异有统计学意义。
- 计算预测与临床试验结合的策略可加速研发并识别安全有效的治疗方案。
核心结论
- 不同剂量JZOL联合AZ均能缩短MPP患儿病程、缓解症状并改善预后。
- 基于网络靶点的计算分析联合三臂随机对照试验可加速研发进程并识别安全有效的治疗组合。
研究设计与样本
- 研究包含基于网络靶点的机制分析及随机、双盲、三臂、平行对照、多中心临床研究。
- 临床试验比较不同剂量JZOL联合AZ治疗儿童MPP的协同效应与安全性。
- 临床试验注册号:ChiCTR1800019007。
主要发现
- 临床恢复中位时间:双倍剂量组5天、常规剂量组6天、安慰剂组8天,组间差异有统计学意义。
- 完全退热时间、咳嗽/咳痰缓解时间、胸片改善有效率及中医证候治愈率组间差异均有统计学意义。
- 机制分析涉及激素反应、细胞分化与迁移、信号转导、氧与缺氧反应四个模块,以TNF信号通路调控为中心。
临床怎么用
- 在临床中可考虑JZOL联合AZ治疗儿童MPP以缩短病程和缓解症状。
- 双倍剂量与常规剂量JZOL联合AZ均显示疗效,具体剂量选择需结合临床实际。
- 治疗过程中需观察临床应用的安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mycoplasma pneumoniae pneumonia (MPP) is a common type of pneumonia among school-aged children and adolescents. Jinzhen Oral Liquid (JZOL) and Azithromycin (AZ) are commonly used treatments in traditional Chinese medicine (TCM) and Western medicine, respectively. There are several clinical and basic research reports on their solo effect against MPP, enabling their combined treatment to become possible. However, the mechanisms and specific pharmacodynamics of their combined therapy remain unclear. In this study, we conducted a mechanistic analysis of the combination of JZOL and AZ based on network target, elucidating their modular network regulatory mechanisms. The modular mechanisms involve four modules, including hormone response, cell differentiation and migration, signal transduction, oxygen and hypoxia response, centered by TNF signaling pathway-mediated regulation. Under the instruction of computational analysis, we conducted a randomized, double-blind, three-armed, parallel-controlled, multicenter clinical study of different doses of JZOL combined with AZ for the treatment of MPP in children. The objective of clinical research is to evaluate the synergistic effect of different doses of JZOL combined with AZ in the treatment of children with MPP, shortening the course of disease and improving prognosis, while observing the safety of clinical application. At the study endpoint, the median time to clinical recovery showed statistically significant differences (The double-dose group lasts for 5 days, the regular-dose group lasts for 6 days, and the placebo group lasts for 8 days), which were also observed between groups for time to complete fever remission, time to relief of cough/phlegm, effective rate of chest X-ray improvement, and rate of healing of TCM symptoms. Different doses of JZOL combined with AZ have shown the effects of shortening the course of the disease, relieving the symptoms, and improving the prognosis. The research program composed of computational prediction and clinical trials can significantly accelerate the research and development process and identify more effective treatment with good safety, which is worthy of clinical promotion. Chinese Clinical Trial Registry ChiCTR1800019007.
引用
- Zhong C, Liu Q, Guo S, et al. A computational-based new treatment strategy with three-armed RCT on Mycoplasma pneumoniae pneumonia in children. Chin Med. 2025. PMID: 40597150. doi:10.1186/s13020-025-01149-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。